Category: Advances in LLM
Should Ponatinib Be the Standard-of-Care Tyrosine Kinase Inhibitor in Ph+ ALL?
H&O How common is Philadelphia chromosome–positive (Ph+) acute lymphocytic leukemia (ALL)? EJ The Ph+ form of ALL is characterized by the presence of the t(9;22) translocation […]
Is Luspatercept the New Standard of Care in Transfusion-Dependent Low-Risk Myelodysplastic Syndromes?
H&O What is luspatercept, and how does it work for patients who have anemia associated with transfusion-dependent low-risk myelodysplastic syndromes (LR-MDS)? GCM Luspatercept (Reblozyl, Celgene/BMS) is […]
Can We Cure Ph+ ALL Without Chemotherapy or Transplant?
H&O What is Philadelphia chromosome–positive (Ph+) acute lymphoblastic leukemia (ALL), and how is it typically managed? RF Ph+ ALL is the most frequent genetic ALL subgroup […]
Pilot Data on Axicabtagene Ciloleucel for CNS Lymphoma
H&O Could you describe the impetus for and design of your pilot study on axicabtagene ciloleucel for CNS lymphoma? CJ When lymphomas that involve the central […]
The Development of Menin Inhibitors in AML and ALL
H&O What are menin inhibitors, and how do they function in the context of acute myeloid leukemia/acute lymphoblastic leukemia? GI Menin inhibitors are a new form […]
Epcoritamab, a Promising Therapy for Richter Syndrome?
H&O What defines Richter syndrome? AK Richter syndrome (RS), also known as Richter transformation, refers to the development of an aggressive lymphoma in the setting of […]
The Use of Glofitamab in Relapsed Diffuse Large B-Cell Lymphoma
H&O What is glofitamab, and how does it work for patients with relapsed and refractory (R/R) diffuse large B-cell lymphoma (DLBCL)? LF Glofitamab (Columvi, Genentech) is […]
Update on the CAPTIVATE Trial of Ibrutinib Plus Venetoclax
H&O Could you describe the impetus for and design of the CAPTIVATE trial? TS The large, multicenter, phase 2 CAPTIVATE trial focused on patients with chronic […]
Mosunetuzumab, the First Bispecific Approved for Follicular Lymphoma
H&O What is mosunetuzumab (Lunsumio, Genentech) and how does it work? LEB Mosunetuzumab is a bispecific antibody-based T-cell engager with 2 binding sites. Unlike conventional monoclonal […]
Is Blinatumomab Now Standard of Care Consolidation for Patients With ALL?
H&O What is blinatumomab and how does it work in treating acute lymphocytic leukemia (ALL)? SL Blinatumomab (Blincyto, Amgen), which is classified as a bispecific antibody, […]
Quizartinib, the Next FLT3 Inhibitor
H&O What are FMS-like tyrosine kinase 3 (FLT3) inhibitors, and how have they affected the treatment of patients with acute myeloid leukemia (AML)? JC FLT3 mutations […]
Momelotinib, the Next JAK2 Inhibitor?
H&O What is momelotinib and how does it work? LM Momelotinib is a selective inhibitor of Janus kinase 1 (JAK1), JAK2, and activin A receptor type […]
Zandelisib and B-Cell Lymphomas
H&O How does zandelisib work? AZ Zandelisib is a phosphoinositide 3-kinase delta (PI3K-δ) inhibitor with a long half-life. PI3K comes in multiple isoforms, including alpha, beta, […]
Noncovalent BTK Inhibitors in B-Cell Lymphoma
H&O What are the limitations of standard (covalent) BTK inhibitors in B-cell malignancies? CC The 2 major limitations of covalent Bruton’s tyrosine kinase (BTK) inhibitors are […]
Optimizing the Benefits of BCMA-Targeted CAR T-Cell Therapy in Multiple Myeloma
H&O Why is the B-cell maturation antigen (BCMA) a good target for chimeric antigen receptor (CAR) T-cell therapy in multiple myeloma? SL BCMA is an important […]
Targeting the Microbiome to Improve Outcomes in Stem Cell Transplant
H&O What are the characteristics of a healthy microbiome? DP A healthy microbiome is dynamic and diverse. It consists of many different types of commensal bacteria—predominantly […]
Key Points From the SHINE Trial in Mantle Cell Lymphoma
H&O Could you provide some background on mantle cell lymphoma? JT Mantle cell lymphoma is an uncommon type of lymphoma. It represents approximately 6% of non-Hodgkin […]
Advances in the Classification and Management of Patients With T-Cell Lymphoma
H&O What are the most common types of T-cell lymphoma? LP T-cell lymphoma is a heterogeneous group of disorders that encompass many subtypes. T-cell lymphomas that […]
Hyper-CVAD–Based Regimens in Adult Patients With Acute Lymphoblastic Leukemia
H&O How was the hyper-CVAD regimen originally used? EJ The hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (hyper-CVAD) regimen was developed by Kantarjian and colleagues at MD […]
The Future Role of Bispecific Antibodies in Lymphoma
H&O What is the mechanism of action of bispecific antibodies? JA Bispecific antibodies aim to harness the power of the immune system. These treatments are monoclonal […]